Psychedelic assisted therapy is rebuilding on narrower, more rigorous trial designs
Dr. Dereck Mush, MD, MBA
Compass Pathways
Mental health care company developing psilocybin-based therapy for treatment-resistant depression.
What they do
Compass Pathways is a biotechnology company focused on developing psilocybin-assisted therapy. The company conducts clinical trials and builds digital tools to train therapists and support patients undergoing treatment for treatment-resistant depression and PTSD.
The record
- Vertical
- Mental & Behavioural Health
- Sub-segment
- Psychedelic-assisted therapy
- Product type
- Diagnostics
- Stage
- Public
- Headquarters
- London, United Kingdom
- Region
- Europe
- Founded
- 2016
- Total funding
- $116M raised
Notable investors: Founders Fund, McAfee Capital, ATAI Life Sciences.
Also in Mental & Behavioural Health
Related on The Signal
Dr. Dereck Mush, MD, MBA
A CDMO partnership shows how gene therapy manufacturing is scaling for chronic disease
Dr. Dereck Mush, MD, MBAThe HealthTech Signal
GLP-1 drugs are excellent at losing weight. The muscle question is where healthspan gets decided
GLP-1 drugs are excellent at losing weight. The muscle question is where healthspan gets decided
Dr. Dereck Mush, MD, MBA
State Medicaid programmes are quietly becoming a testing ground for digital therapeutics coverage
Dr. Dereck Mush, MD, MBA